These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16995866)

  • 1. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs.
    Gardiner SJ; Gearry RB; Roberts RL; Zhang M; Barclay ML; Begg EJ
    Br J Clin Pharmacol; 2006 Oct; 62(4):453-6. PubMed ID: 16995866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.
    Chouchana L; Narjoz C; Roche D; Golmard JL; Pineau B; Chatellier G; Beaune P; Loriot MA
    Pharmacogenomics; 2014 Apr; 15(6):745-57. PubMed ID: 24897283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis.
    Nguyen TM; Daubard M; Le Gall C; Larger M; Lachaux A; Boulieu R
    Ther Drug Monit; 2010 Aug; 32(4):433-7. PubMed ID: 20479703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides.
    Gardiner SJ; Gearry RB; Burt MJ; Ding SL; Barclay ML
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1238-42. PubMed ID: 18989148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine and breastfeeding: is it safe?
    Sau A; Clarke S; Bass J; Kaiser A; Marinaki A; Nelson-Piercy C
    BJOG; 2007 Apr; 114(4):498-501. PubMed ID: 17261122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
    Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.
    Heneghan MA; Allan ML; Bornstein JD; Muir AJ; Tendler DA
    J Hepatol; 2006 Oct; 45(4):584-91. PubMed ID: 16876902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease.
    Balevic S; Sims CA; Eudy A; Smith V; Clowse M
    Lupus Sci Med; 2024 Jan; 11(1):. PubMed ID: 38176699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease.
    Kopylov U; Amre D; Theoret Y; Deslandres C; Seidman EG
    J Pediatr Gastroenterol Nutr; 2014 Oct; 59(4):511-5. PubMed ID: 24918978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
    Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
    Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.